🎄 Merry Christmas from Orion Therapeutics, Inc.🎄 As we celebrate this joyous season, we want to extend our heartfelt gratitude to our partners, colleagues, and supporters who have been part of our journey this year. Your collaboration and encouragement inspire us to continue innovating and pushing the boundaries of genetic medicine. May your holiday season be filled with warmth, joy, and precious moments with loved ones. Here’s to a new year of breakthroughs, growth, and shared successes! Merry Christmas and Happy New Year! – The Orion Therapeutics Team #lnp #geneticmedicine #RNA #siRNA #geneediting #merrychristmas #happynewyear
Orion Therapeutics, Inc.
Biotechnology Research
Knoxville, Tennessee 1,187 followers
Platform technology providing targeted delivery of RNA aimed at curing and preventing previously undruggable disease.
About us
The recent success of mRNA vaccines in the fight against COVID-19 has placed RNA-based pharmaceutical strategies center-stage in the biotech community. This medical milestone marks an inflection point in human history that will revolutionize the pharmaceutical industry from top-to-bottom, providing cures for the incurable and improving the overall quality of life for patients across the globe. However, the primary challenge hindering commercialization of these RNA drugs is the issue of DELIVERY. There are nearly 1500 nucleic acid-based drugs (RNA or DNA) currently in preclinical development for a wide range of disease applications including cancer, cardiovascular disease, HIV, Alzheimer's, and certain forms of blindness to name a few. Despite the extensive investment in these technologies over the last decade, only a handful of RNA drugs have been approved for human use. The major factor preventing translational success in these drug development programs is the lack of a safe, targeted, and efficacious delivery system for RNA drug payloads. The most successful delivery formulations to-date are represented by lipid nanoparticles (LNP) exemplified in mRNA vaccines developed by Pfizer-BioNTech and Moderna. These LNP technologies rely on unnatural lipid chemistries that limit utility of mRNA drug platforms and pipeline from a safety and efficacy standpoint. Also, many of our competitors within the non-viral RNA delivery space have been embroiled in litigation over intellectual property that is entangled in advanced LNP formulation processes. Orion has developed a targeted LNP delivery platform that packages and protects nucleic acid drug payloads for safe and effective use in human patients. Our delivery platform is agnostic to both RNA type/class and disease indication with nearly limitless utility in the RNA therapeutics and vaccine market.
- Website
-
https://www.orionthx.com/
External link for Orion Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Knoxville, Tennessee
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
2641 Osprey Vista Way
150A
Knoxville, Tennessee 37920, US
Employees at Orion Therapeutics, Inc.
-
Samuel Mattern-Schain
organic chemist with expertise in cellular biology and preclinical nanodrug development
-
Leanne Minall
VP of Science
-
Mark Wienhold
Lead Scientist
-
Deidra Mountain, PhD
Professor, Scientific Director of Vascular Research, University of Tennessee Graduate School of Medicine; Co-Founder, Director of Vascular…
Updates
-
Supporting early-stage innovation and building partnerships across borders is key to advancing breakthrough science. Orion Therapeutics, Inc. was honored to be part of the inaugural SCbio cohort Demo Day as an alum of the 2022 MassBio cohort. MassBio has been instrumental in supporting Orion through our early stages, and we’re so grateful for their leadership and global network. It’s exciting to see initiatives like SCbio Drive emerging outside of Massachusetts, showing that supporting innovation anywhere benefits patients everywhere. Thank you, MassBio and SCbio, for fostering collaboration and innovation that will shape the future of patient care. #Innovation #Collaboration #Biotech #SCbioDrive #MassBioDrive Kendalle Burlin O'Connell, Esq. Jennifer Zachry, PhD Michael McCaman, PhD Jason Cordeiro
CEO & President, MassBio | Chair, Bioversity | Board, The Boston Foundation | Vice Chair, American Cancer Society (ACS) Eastern New England | Board, MassBioEd Foundation
Talk about supporting early-stage innovation and partnering across borders to advance potentially breakthrough science. An excellent visit with SCbio for the inaugural #SCbioDrive cohort’s Demo Day. We celebrated the incredible companies and founders who went through the South Carolina version of Drive and brought some of our #MassBioDrive alum with us. I love showing off the teams we’ve helped along the way. This partnership with our friends in SC is built on the premise that MassBio’s support of innovation anywhere benefits patients everywhere. And that our nearly 40 years of experience and global network can help growing ecosystems mature. #patientdriven
-
-
-
-
-
+1
-
-
We are honored to share this article highlighting Michael McCaman, whose remarkable contributions to the world of gene editing and genetic medicine have been pivotal in the success of Orion Therapeutics. Michael's passion, expertise, and unwavering dedication have not only helped us get off the ground but have also driven meaningful advancements in our field. We are deeply grateful for his partnership and mentorship as we continue to push the boundaries of what's possible in RNA therapeutics. Thank you, Michael, for your invaluable contributions to our journey and to the future of genetic medicine. #lnp #mRNA #drugdelivery #geneticmedicine #entrepreneurship #geneediting
-
We are honored to be the first recipient of investment from the University of Tennessee Research Foundation - UTRF Accelerate Fund. We also send a big thanks to LaunchTN for the matching investment and continued support of our biotech startup here in East TN. Cheers to Eller M Kelliher, Isaiah (Ziggy) Allenlundy, Khrystopher Hatch, Allyn Abadie, Charles Layne, Kusum Rathore, Ph.D., Maha Krishnamurthy, Randy Boyd, Abby Trotter, and Cameron Snow for all of the hard work. Your efforts are much appreciated by the team here at Orion Therapeutics, Inc. #LNP #mRNA #geneticmedicine #universityoftennessee
We're thrilled to announce that Orion Therapeutics, Inc. is the first recipient of the University of Tennessee Research Foundation - UTRF newly established $5M fund dedicated to accelerating groundbreaking tech startups. Orion Therapeutics is pioneering new therapies that target aggressive and hard-to-treat tumors. Their innovative approach and promising research make them the perfect inaugural recipient of this transformative fund. This milestone is a testament to the University of Tennessee's commitment to fostering innovation and supporting startups that have the potential to make significant impacts in their respective fields. We're proud to support Orion Therapeutics through the Spark Incubator Program, where we nurture and accelerate the growth of advanced tech startups. A big thank you to the Knoxville News Sentinel for the coverage!
First recipient of Tennessee's $5M startup fund has 'limitless' drug potential
knoxnews.com
-
🚀 Proud to Share Exciting News!🚀 Orion Therapeutics is thrilled to announce a $150,000 Accelerate Fund investment from University of Tennessee Research Foundation - UTRF to advance our next-gen RNA medicines and delivery platform. We are deeply grateful for UTRF's support and the participation of LaunchTN in this investment round! A big thanks to Maha Krishnamurthy and Kusum Rathore, Ph.D. for their efforts and support on this investment! #Investment #Biotech #OrionTherapeutics #UTRF #LaunchTN #RNAMedicines #HealthcareInnovation #LNP #rnatherapy #geneticmedicine
🚀 Exciting News! 🚀 UTRF is thrilled to announce our first Accelerate Fund investment in Orion Therapeutics, Inc., a pioneering biotechnology startup at the forefront of developing next-generation RNA medicines. With a novel drug delivery system, Orion Therapeutics is poised to make significant advancements in the field of RNA therapeutics. Co-investing with LaunchTN, we are proud to invest $150,000 each. This partnership underscores our commitment to supporting innovative startups. We look forward to seeing the incredible impact Orion Therapeutics will have in making life and lives better. #Investment #StartupSuccess #UTRF #LaunchTN #OrionTherapeutics University of Tennessee System The University of Tennessee Graduate School of Medicine The University of Tennessee Health Science Center
-
-
We are excited to announce that Orion Therapeutics has received investment from the “InvestTN” fund, managed by Launch TN. This support is pivotal for our work in developing next-generation RNA medicines with our proprietary lipid nanoparticle delivery platform. A big thank you to LaunchTN for fostering a thriving startup environment in Tennessee, especially for biotech companies. Your belief in our mission is helping us advance the future of RNA therapeutics! #lnp #RNA #investTN #LaunchTN #UTRF #geneticmedicine #genetherapy #biotech
LaunchTN announced seven additional portfolio companies for the $70-million “InvestTN” fund. Congratulations to AnyCreek Nisolo One of None, Orion Therapeutics, Inc., Oversite SoBet SpendCare, Inc. 👏 More: https://lnkd.in/eaxta5Bw
-
-
While mRNA modification has significantly mitigated inflammation and toxicity in RNA therapies, leading to successful market entries, the same success has not been fully mirrored in lipid-based delivery systems. The toxicity and inflammatory responses associated with these delivery vehicles remain critical hurdles, as evidenced by numerous clinical trial failures involving LNPs and other advanced delivery systems. At Orion Therapeutics, our cutting-edge lipopeptide delivery platform addresses these challenges by enhancing the therapeutic index and reducing toxicity, offering a robust solution for the most challenging hurdles in genetic medicine - The Issue of Delivery. Recognizing the potential of our platform to address a wide range of therapeutic areas, we are actively seeking opportunities to out-license our technology. This strategic approach allows us to collaborate with partners aiming to harness the power of RNA therapies in their own pipelines, expanding the impact of our innovations across the biotech landscape and contributing to the advancement of genetic medicine. Join us at the MassBio Align Summit to explore how our technology is setting new benchmarks; we will be presenting at 10:50 AM tomorrow in the East Tower room. #AlignSummit24 #AlignSummit #AIDrugDiscovery #LNP #RNA
Our second Align Summit is April 25 at the Royal Sonesta Boston, sponsored by Eli Lilly and Company. This partnering event connects funders looking to invest in innovation with startups developing the most ambitious and promising science. With our partners McKinsey & Company and Locust Walk, we’ve assembled 50+ pureplay biotech and artificial intelligence companies focused on R&D to present: https://lnkd.in/eTVFud8w. Read more about how MassBio is nurturing the Massachusetts ecosystem and advancing therapies closer to patients at Align Summit in this post from Chief Operating & Innovation Officer Jason Cordeiro: https://lnkd.in/e24U6TFw. #AlignSummit #AlignSummit24 #AIDrugDiscovery
Align Summit: Pairing ambitious science with funding partners - MassBio
https://www.massbio.org
-
We're honored and excited to be named finalists in the 2024 PYA Ballard Innovation Award! This recognition is a testament to our team's hard work and dedication to advancing RNA therapeutics. We look forward to the live pitch competition this week and the opportunity to share how our technology can make a significant impact in the healthcare industry. Join us in celebrating this milestone and stay tuned for more updates from Orion Therapeutics! #PYABallardInnovationAward #Innovation #Healthcare #RNAtherapeutics #OrionTherapeutics #LNP #RNA #Geneticmedicine
PYA is pleased to announce the five 2024 PYA Ballard Innovation Award finalists. In its fourth year, the award is the largest gift of cash and in-kind services available to entrepreneurs and start-ups in the East Tennessee region! Congratulations to Authentrics.ai, Orion Therapeutics, Inc., Safire Technology Group, Inc., Statherós®, and Whisper Aero 👏 RSVP for the pitch competition and award ceremony on April 10: pyapc.com/Ballard
-
Orion Therapeutics, Inc. reposted this
Congratulations to RESI South Innovator’s Pitch Challenge (IPC) finalist, Orion Therapeutics, Inc.! President & CEO, Trey Fisher, PhD will pitch to a panel of #investor judges on March 25 in Atlanta. Register for IPC: https://lnkd.in/dhVft4c #RESI #RESISOUTH #RESIATLANTA #Startups #Investment #Pitch #Earlystage #Fundraising #Healthcare #Lifescience BIO Alabama, BioFlorida, Inc., Georgia Bio, Life Science Tennessee, NC Life Sciences Organization, SCbio, Virginia Bio
-
-
Orion Therapeutics, Inc. reposted this
We're thrilled to announce that Orion Therapeutics has been named a winner in the NIH TARGETED Phase 1 Challenge! 🏆 At Orion Therapeutics, we're driven by a mission to revolutionize medicine, and this grant is a leap forward in our quest. We are focused on achieving precise delivery of genome editing tools to extrahepatic disease sites and conquering one of the toughest barriers in therapy, the blood-brain barrier. Our goal is clear: to bring innovative gene therapy treatments to areas where they are needed most. Here's to making targeted gene editing a reality! #OrionTherapeutics #lnp #rnatherapeutics #geneediting #Innovation #GenomeEditing #NIHTARGETEDChallenge #HealthTech #targetedtherapy https://lnkd.in/erTQ6yBJ
National Institutes of Health Announces Phase 1 Winners of the $6M TARGETED Challenge
freelancer.com